OBR OncologyGilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023

ASCO 2023 abstracts: a glimpse into groundbreaking advancements in the oncology field.

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Gilead Sciences and Kite Oncology are set to present 30 abstracts. Their data underscores their leadership in hard-to-treat cancers, notably metastatic breast cancer. In addition, they highlight a growing presence in lung cancer and other tumor types.

Trodelvy® (sacituzumab govitecan-hziy) emerges as a promising treatment for HR+/HER2- metastatic breast cancer (mBC) with the final overall survival (OS) results from the Phase 3 TROPiCS-02 study. Its efficacy extends to metastatic urothelial cancer (UC) and advanced endometrial cancer, reinforcing its pan-tumor potential.

Moreover, Yescarta® (axicabtagene ciloleucel) offers a ray of hope for adult patients with relapsed/refractory large B-cell lymphoma (LBCL). Notably, this CAR T-cell therapy demonstrates a statistical improvement over standard care in overall survival, marking a significant medical breakthrough.

Gilead’s oncology pipeline, particularly for lung cancer, is expanding. The ongoing late-stage development program evaluates Trodelvy in non-small cell lung cancer (NSCLC). Also, the updated interim analysis of ARC-7, evaluating domvanalimab in first-line NSCLC, will be presented.

Presentations at ASCO 2023 will also share trial updates from ongoing studies in lung cancer, triple-negative breast cancer, UC, and other solid tumors. In summary, these ASCO 2023 abstracts signify a bold leap in oncology, underlining the potency of transformative science in cancer treatment.